Freedom of Information request on the marketing authorisations for Antepsin (FOI 21/1065)
Published 25 February 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-20-september-2021/freedom-of-information-request-on-the-marketing-authorisations-for-antepsin-foi-211065
24th September 2021
FOI 21/1065
Dear
Thank you for your email.
The reason for the cancellation of each of the marketing authorisations for Antepsin is provided below:
PL 12185/0010 ANTEPSIN 1G/5ML – This was cancelled at the request of the MAH on 27 September 2019
PL 12185/0009 ANTEPSIN 500MG - This was cancelled at the request of the MAH on 29 December 2005
PL 12185/0008 ANTEPSIN 1G – This licence was cancelled because of Sunset Clause provisions on 30 May 2019.
PL 00607/0045 ANTEPSIN TABLETS – This licence was cancelled but we have no further records on when or why this occurred.
PL 00011/0176 ANTEPSIN TABLETS 1G - Change of Authorisation Holder (CoA) to PL 12185/0008, granted 01 December 1998
PL 00011/0175 ANTEPSIN TABLETS 500MG – Change of Authorisation Holder (CoA) to PL 12185/0009, granted 01 December 1998
PL 00011/0160 ANTEPSIN SUSPENSION 1 GRAM/5ML – Change of Authorisation Holder (CoA) to PL 12185/0010, granted 01 December 1998
Kind regards,
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU